<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02078284</url>
  </required_header>
  <id_info>
    <org_study_id>S-12-04</org_study_id>
    <secondary_id>CPP1-05</secondary_id>
    <nct_id>NCT02078284</nct_id>
  </id_info>
  <brief_title>Phase 1 Safety Study of Dimethyl Sulfoxide Cryopreserved Platelets</brief_title>
  <official_title>Dose Escalation Study Evaluating the Safety of Dimethyl Sulfoxide Cryopreserved Platelets Compared With Liquid Stored Platelets in Patients With Uncontrolled Bleeding</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>U.S. Army Medical Research and Materiel Command</agency>
      <agency_class>U.S. Fed</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>U.S. Army Medical Research and Materiel Command</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study is to evaluate the safety of intravenous (IV) infusion of dimethyl sulfoxide
      (DMSO) cryopreserved platelets (CPP) in participants with World Health Organization (WHO)
      Grade 2 bleed in spite of receiving a transfusion of liquid stored platelets (LSP) in the
      past 48 hours by collecting adverse events (AEs) and by evaluating coagulation-related
      parameters to assess the evidence of any thrombotic events after CPP or LSP transfusion.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>August 2014</start_date>
  <completion_date type="Actual">August 2016</completion_date>
  <primary_completion_date type="Actual">August 2016</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of adverse events</measure>
    <time_frame>6 days after transfusion</time_frame>
    <description>Clinical laboratory [chemistry (serum creatinine, lactate dehydrogenase (LDH), and troponin, and hematology (hemoglobin and hematocrit)] parameters, physical examination findings, electrocardiogram (ECG), and vital signs.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number thrombotic events</measure>
    <time_frame>6 days after transfusion</time_frame>
    <description>Participants with any signs or symptoms of thrombotic events.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Pre and post CPP transfusion coagulation parameters</measure>
    <time_frame>6 days after transfusion</time_frame>
    <description>Number and percentage of participants with pre and post CPP transfusion coagulation findings. These include fibrinogen, D-dimer, prothrombin fragments 1 + 2, thrombin-anti-thrombin (TAT), anti-thrombin (AT), prothrombin time (PT), and activated partial thromboplastin time (aPTT) findings</description>
  </primary_outcome>
  <number_of_arms>8</number_of_arms>
  <enrollment type="Actual">28</enrollment>
  <condition>Thrombocytopenia</condition>
  <arm_group>
    <arm_group_label>Cohort 1 with 0.5 units of CPP</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>A single 30 to 60 minute intravenous (IV) infusion of 0.5 unit of dimethyl sulfoxide (DMSO) cryopreserved platelets (CPP)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 1 with 1 unit of LSP</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>A single 30 to 60 minute intravenous (IV) infusion of 1 unit of liquid stored platelets (LSP)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 2 with 1 unit of CPP</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>A single 30 to 60 minute intravenous (IV) infusion of 1 unit of dimethyl sulfoxide (DMSO) cryopreserved platelets (CPP)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 2 with 1 unit of LSP</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>A single 30 to 60 minute intravenous (IV) infusion of 1 unit of liquid stored platelets (LSP)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 3 with 2 units of CPP</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>A single 30 to 60 minute intravenous (IV) infusion of 2 units of dimethyl sulfoxide (DMSO) cryopreserved platelets (CPP)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 3 with 1 unit of LSP</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>A single 30 to 60 minute intravenous (IV) infusion of 1 unit of liquid stored platelets (LSP)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 4 with 3 units of CPP</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>A single 30 to 60 minute intravenous (IV) infusion of 3 units of dimethyl sulfoxide (DMSO) cryopreserved platelets (CPP)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 4 with 1 unit of LSP</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>A single 30 to 60 minute intravenous (IV) infusion of 1 unit of liquid stored platelets (LSP</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>CPP</intervention_name>
    <description>One unit of frozen CPP contains approximately 3.4 x 10^11 irradiated platelets and approximately 6% DMSO in sterile 0.9% sodium chloride solution (total volume of 20 mL to 35 mL) stored frozen at ≤ -65°C.</description>
    <arm_group_label>Cohort 1 with 0.5 units of CPP</arm_group_label>
    <arm_group_label>Cohort 2 with 1 unit of CPP</arm_group_label>
    <arm_group_label>Cohort 3 with 2 units of CPP</arm_group_label>
    <arm_group_label>Cohort 4 with 3 units of CPP</arm_group_label>
    <other_name>dimethyl sulfoxide (DMSO) cryopreserved platelets (CPP)</other_name>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>LSP</intervention_name>
    <arm_group_label>Cohort 1 with 1 unit of LSP</arm_group_label>
    <arm_group_label>Cohort 2 with 1 unit of LSP</arm_group_label>
    <arm_group_label>Cohort 3 with 1 unit of LSP</arm_group_label>
    <arm_group_label>Cohort 4 with 1 unit of LSP</arm_group_label>
    <other_name>liquid stored platelets (LSP)</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Male or female, at least 18 years of age.

          -  Ability to comprehend the study procedures and signed informed consent.

          -  If pre-menopausal female, must have a negative serum pregnancy test, and, if of child
             bearing potential, must be using an acceptable method of contraception.

          -  Diagnosed with any the following: acute leukemia (ALL or AML), chronic leukemia (CML,
             CLL, CMML, or hairy cell leukemia), myelodysplasia, aplasia, hematopoietic or
             non-hematopoietic solid tumor, or therapy (chemotherapy or radiation) induced bone
             marrow aplasia or hypoplasia. Either autologous or allogeneic bone marrow transplant
             or peripheral or cord blood stem cell recipients may be enrolled.

          -  WHO grade 2 or greater bleeding.

          -  LSP transfusion within the previous 48 hours.

        Exclusion Criteria:

          -  Acute or chronic DIC as evidence by D-dimer greater than 8 μg/mL and fibrinogen less
             than 100 mg (0.1 g)/dL. Both criteria must be met. If data are in the medical record
             for fibrin degradation products (FDPs), then FDP must be &lt;=40 μg/mL (FDP &gt;40 μg/mL is
             indicative of DIC).

          -  PT or aPTT &gt; 1.3 times the upper limit of normal for the laboratory.

          -  History of major operative procedures that required general anesthesia in the past 2
             weeks.

          -  History of any prior major unprovoked thrombotic events and/or known inherited
             disorder of coagulation or platelet function (by history) (not to include clots in
             catheters, etc).

          -  A history or diagnosis of immune thrombocytopenia, thrombotic thrombocytopenic
             purpura, or hemolytic uremic syndrome.

          -  Females who are breastfeeding.

          -  Veno-occlusive disease or possible veno-occlusive disease.

          -  Receiving active, inpatient treatment with anti-platelet drugs and/or full
             anticoagulation therapy. Note: a heparin flush may be given daily and before and after
             blood draws to patients with a central line to keep the line patent.

          -  Subject previously enrolled in this study and received a study transfusion.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Sherrill J Slichter, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Bloodworks (Puget Sound Blood Center)</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Terry B Gernsheimer, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Washington, Division of Hematology</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Zbigniew Szczepiorkowski, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Center for Transfusion Medicine Research, Lebanon, NH</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Jose A Cancelas-Perez, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Hoxworth Blood Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Dartmouth-Hitchcock Medical Center</name>
      <address>
        <city>Lebanon</city>
        <state>New Hampshire</state>
        <zip>03756</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hoxworth Blood Center</name>
      <address>
        <city>Cincinnati</city>
        <state>Ohio</state>
        <zip>45267</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Puget Sound Blood Center</name>
      <address>
        <city>Seattle</city>
        <state>Washington</state>
        <zip>98104</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Washington, Division of Hematology</name>
      <address>
        <city>Seattle</city>
        <state>Washington</state>
        <zip>98195</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>August 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>February 26, 2014</study_first_submitted>
  <study_first_submitted_qc>February 28, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 5, 2014</study_first_posted>
  <last_update_submitted>August 12, 2016</last_update_submitted>
  <last_update_submitted_qc>August 12, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">August 15, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>platelet transfusion</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Thrombocytopenia</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Dimethyl Sulfoxide</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

